On This Page:

The FlashGM Study is a national multicenter clinical trial for Indigenous Australians with type 2 diabetes funded by the National Health and Medical Research Council. The trial will investigate if a new device called flash glucose monitoring will improve sugar levels compared to finger prick testing. The study consists of 6 visits across 6 months. Indigenous Australians with type 2 diabetes on injectable therapy, and with persistent high blood glucose levels (HbA1c >7.5%), will be randomly assigned to use a flash glucose monitor or standard care (finger pricking) for 6 months.

Participants who were randomly assigned to finger pricking will be offered flash glucose monitoring for 6 months at the end of the trial. The anticipated outcomes will be a lower, clinically significant HbA1c level with flash glucose monitoring, achieving blood glucose targets, fewer low blood sugar episodes, reduced costs, and improved quality of life.

The research will likely lead to major, cost-effective health gains for Indigenous Australians, and significantly improved health-service delivery for Indigenous and other high-risk Australians. The trial aims to recruit 350 Indigenous Australians with type 2 diabetes across multiple sites in Australia

Who can be involved?

  1. Indigenous Australian
  2. Confirmed diagnosis of type 2 diabetes
  3. Age ≥ 18 years
  4. HbA1c >7.5% (58 mmol/mol) from either a recent test or sample at screening
  5. Medicated with the same type of injectable therapies ± oral hypoglycaemic agents, for at least 3 months prior to screening:
    I. Insulin alone or with (±) oral agents
    II. GLP1 analogues ± oral agents
    III. GLP1 analogues and insulin ± oral agents.

For further information, please contact:

Name: Mariam Hachem
Phone: (03) 94962645
Email: flash-study@unimelb.edu.au

https://blogs.unimelb.edu.au/flashgmstudy/

This research project has been approved by St. Vincent’s Human Research Ethics Committee (HREC) 188/20